Aerogen Solo - Disposable nebulizor for aerosol delivery
The Aerogen Solo is the only closed-circuit aerosol drug delivery system, designed for the safety of both the patient and the caregiver.
The Aerogen® Solo System is a portable medical device for single patient use that is intended to aerosolise physician-prescribed medications for inhalation that are approved for use with a general purpose nebuliser. This device can be used by patients on and off mechanical ventilation or other positive pressure breathing assistance.
The Aerogen Solo can be used for 28 days based on a typical usage of 4 intermittent treatments per day. For continuous use, the Aerogen Solo is qualified for a maximum of 7 days.
- Safety: Aerogen is the only closed-circuit aerosol drug delivery system that mitigates the transmission of patient-generated infectious aerosol.
- Effective: Aerogen effectively delivers inhalation medication with 5x more medication delivered to the lungs compared to a jet nebulizer.
- Trusted: Aerogen is recommended for use by many of by the world’s leading mechanical ventilation companies.
Description
More Effective, More Control
The Aerogen Solo delivers more inhaled medication to the lungs,4 in less time,5 with less residual volume,7 compared to jet nebulizers, giving confidence in a more effective and controlled treatment.
Multiple Therapies
The Aerogen Solo delivers more effective medication throughout the hospital through mechanical ventilation and non-invasive support such as non-invasive ventilation (NIV), high flow therapies (HFNC) and spontaneously breathing patients.1-7
Lowering Risk of Exposure
The medication reservoir is isolated from the breathing circuit which minimizes nebulization of contaminated fluids.1 The risk of exposure to bioaerosols is reduced because the need to open the circuit is eliminated.8
Lung Recruitment Maintained
The Aerogen Solo is uniquely designed remaining in place during ventilation.8 This closed system requires minimal management and can be left inline reducing staff handling and workload.7,10
Simple & Quiet
Easy to set up and virtually silent operation, with no added flow required.7
6x More medication delivered for spontaneously breathing patients
Technical Services
1. Dunne RB, Shortt S. Comparison of bronchodilator administration with vibrating mesh nebulizer and standard jet nebulizer in the emergency department. Am J Emerg Med 2018; 4: 641–646. 2. Moody GB, Luckett PM, Shockley CM, Huang R, Ari A. Clinical Efficacy of Vibrating Mesh and Jet Nebulizers With Different Interfaces in Pediatric Subjects With Asthma. Respir Care 2020; : respcare.07538. 3 .Cantu T, et al. Quality Improvement Project to Compare Vibrating Mesh Nebulizer Therapy With Hour Long Jet Nebulizer Therapy for Albuterol Delivery in Asthma and Reactive Airway Disorder Patients in a Pediatric Emergency Department. Respiratory Care October 2019, 64 (Suppl 10) 3238888. 4. Dugernier J, Hesse M, Vanbever R, Depoortere V, Roeseler J, Michotte JB et al. SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study. Pharm Res 2017; 34: 290–300
5. Hickin S, Mac Loughlin R, Sweeney L, Tatham A, Gidwani S. Comparison of mesh nebulizer versus jet nebulizer in simulated adults with chronic obstructive pulmonary disease. Poster Coll Emerg Med Clin Excell Conf 2014. 6. Abdelrahim ME, Plant P, Chrystyn H. In-vitro characterisation of the nebulised dose during non-invasive ventilation. J Pharm Pharmacol 2010;62(8):966–972 7.Aerogen Instruction Manual 8. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir. Med. 2020; 167. doi:10.1016/j.rmed.2020.105987. 9. Dugernier J, Reychler G, Wittebole X, et al. Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. Ann Intensive Care 2016;6(1):73 10. Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience. J. Crit. Care. 2020; 58: 56–57.